Latest Lapatinib Stories
PHILADELPHIA, Jan. 29 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
Provides oral regime for hormone positive and HER2-positive advanced breast cancer SILVER SPRING, Md., Jan. 29 /PRNewswire-USNewswire/ -- The U.S.
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies.
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive.
LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERBÂ® (lapatinib) plus HERCEPTINÂ® (trastuzumab).
Finland, November 11 /PRNewswire/ -- - This is a third party press release.
One of the first of a series of trials to investigate the use of sorafenib â€“ a targeted anti-cancer drug â€“ for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.
NEW YORK, Sept.
Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients.
SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia.
- The governor of a province or people.